We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
+12.9%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$240M
AUM Growth
+$986K
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
9
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TRDA icon
1
Entrada Therapeutics
TRDA
$227M
$64.2M 26.74%
4,425,784
DYN icon
2
Dyne Therapeutics
DYN
$4.04B
$57M 23.77%
4,951,303
AMYT
3
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$38.9M 16.21%
2,668,843
ITOS
4
DELISTED
iTeos Therapeutics
ITOS
$37.3M 15.53%
2,738,785
RPTX
5
DELISTED
Repare Therapeutics
RPTX
$22.1M 9.2%
2,242,636
HOWL icon
6
Werewolf Therapeutics
HOWL
$20.8M
$11.1M 4.64%
4,284,172
TCRR
7
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$6.08M 2.53%
4,050,865
HARP
8
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.33M 0.97%
313,139
ONCR
9
DELISTED
Oncorus, Inc.
ONCR
$980K 0.41%
2,849,464

Similar funds

MPM Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, MPM Asset Management held 9 positions worth $240M, up 0.41% from $239M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 0%. MPM Asset Management opened no new positions and made no exits, leaving the 9-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM Asset Management's ten largest holdings make up 100% of its $240M portfolio in Q1 2023.
  • MPM Asset Management opened 0 new positions and closed 0 in Q1 2023.
  • MPM Asset Management's portfolio value rose 0.41% quarter-over-quarter to $240M.

Based on MPM Asset Management's 13F filing for Q1 2023, filed 12 May 2023.